Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ocata Therapeutics Inc (NASDAQ:OCAT)

BATS BZX Real-Time Price
As of 10:56am ET
 +0.02 / +0.23%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Ocata Therapeutics, Inc. is a biotechnology company, engaged in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. It is actively conducting clinical trials for treating dry age-related macular degeneration and Stargardt's macular degeneration, in addition to several clinical and preclinical programs for other ocular therapies. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company's intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy research programs. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA.

Contact Information

Ocata Therapeutics, Inc.
33 Locke Drive
Marlborough Massachusetts 01752
P:(508) 756-1212
Investor Relations:



Other institutional7.54%
Mutual fund holders7.50%
Individual stakeholders1.95%

Top Executives

Paul K. WottonPresident, Chief Executive Officer & Director
Edward H. MylesChief Operating & Financial Officer
Robert P. LanzaChief Scientific Officer
Eddy AngladeChief Medical Officer
Shi-Jiang LuSenior Director-Research